Pheochromocytoma and abdominal paraganglioma

Bucher, 2004, Paraganglioma of the ampulla of Vater: a potentially malignant neoplasm, Scand J Gastroenterol, 39, 291, 10.1080/00365520310007503 Bravo, 2003, Pheochromocytoma: state-of-the-art and future prospects, Endoc Rev, 24, 539, 10.1210/er.2002-0013 Pacak, 2007, Preoperative management of the pheochromocytoma patient, J Clin Endocrinol Metab, 92, 4069, 10.1210/jc.2007-1720 Bravo, 1984, Current concepts. Pheochromocytoma: diagnosis, localization and management, N Engl J Med, 311, 1298, 10.1056/NEJM198411153112007 Bravo, 1991, Pheochromocytoma: new concepts and future trends, Kidney Int, 40, 544, 10.1038/ki.1991.244 Pacak, 2001, Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma, Ann Intern Med, 134, 315, 10.7326/0003-4819-134-4-200102200-00016 Radtke, 1975, Cardiovascular complications of pheochromocytoma crisis, Am J Cardiol, 35, 701, 10.1016/0002-9149(75)90060-0 Prys-Roberts, 2000, Phaeochromocytoma-recent progress in its management, Br J Anaesth, 85, 44, 10.1093/bja/85.1.44 Lonser, 2003, von Hippel-Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4 Eisenhofer, 2001, Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes, J Clin Endocrinol Metab, 86, 1999, 10.1210/jcem.86.5.7496 Eisenhofer, 2008, Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma, Am J Physiol Endocrinol Metab, 295, E1223, 10.1152/ajpendo.90591.2008 Donis-Keller, 1993, Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC, Hum Mol Genet, 2, 851, 10.1093/hmg/2.7.851 Mulligan, 1993, Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A, Nature, 363, 458, 10.1038/363458a0 Carling, 2005, Multiple endocrine neoplasia syndrome: genetic basis for clinical management, Curr Opin Oncol, 17, 7, 10.1097/01.cco.0000148567.29850.31 Bausch, 2007, Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1, J Clin Endocrinol Metab, 92, 2784, 10.1210/jc.2006-2833 Burnichon, 2010, SDHA is a tumor suppressor gene causing paraganglioma, Hum Mol Genet, 19, 3011, 10.1093/hmg/ddq206 Neumann, 2002, Germ-line mutations in nonsyndromic pheochromocytoma, N Engl J Med, 346, 1459, 10.1056/NEJMoa020152 Erlic, 2009, Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients, Clin Cancer Res, 15, 6378, 10.1158/1078-0432.CCR-09-1237 Thompson, 2002, Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases, Am J Surg Pathol, 26, 551, 10.1097/00000478-200205000-00002 Scholz, 2007, Clinical review: Current treatment of malignant pheochromocytoma, J Clin Endocrinol Metab, 92, 1217, 10.1210/jc.2006-1544 Strong, 2008, Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis, Surgery, 143, 759, 10.1016/j.surg.2008.02.007 Rao, 2000, Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment, Hypertension, 36, 1045, 10.1161/01.HYP.36.6.1045 John, 1999, Pheochromocytomas: can malignant potential be predicted?, Urology, 53, 679, 10.1016/S0090-4295(98)00612-8 Proye, 1994, Comparative secretory profiles of benign and malignant pheochromocytomas, Ann Chir, 48, 430 Harari, 2011, Malignant pheochromocytoma: a review, Am J Surg, 201, 693, 10.1016/j.amjsurg.2010.04.012 Agarwal, 2010, Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?, World J Surg, 34, 3022, 10.1007/s00268-010-0744-5 Kudva, 2003, Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience, J Clin Endocrinol Metab, 88, 4533, 10.1210/jc.2003-030720 Sawka, 2003, A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines, J Clin Endocrinol Metab, 88, 553, 10.1210/jc.2002-021251 Hsiao, 1991, Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma, Medicine (Baltimore), 70, 33, 10.1097/00005792-199101000-00003 Taupenot, 2003, The chromogranin-secretogranin family, N Engl J Med, 348, 1134, 10.1056/NEJMra021405 Blake, 2010, Adrenal imaging, AJR, 194, 1450, 10.2214/AJR.10.4547 Havekes, 2010, New imaging approaches to phaeochromocytomas and paragangliomas, Clin Endocrinol (Oxf), 72, 137, 10.1111/j.1365-2265.2009.03648.x Jacobson, 2010, 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis, J Clin Endocrinol Metab, 95, 2596, 10.1210/jc.2009-2604 Timmers, 2009, Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma, J Clin Endocrinol Metab, 94, 4757, 10.1210/jc.2009-1248 Miskulin, 2003, Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma?, Surgery, 134, 918, 10.1016/S0039-6060(03)00416-1 Mihai, 2008, Routine preoperative (123) I-MIBG scintigraphy for patients with phaeochromocytoma is not necessary, Langenbecks Arch Surg/Deutsche Gesellschaft fur Chirurgie, 393, 725, 10.1007/s00423-008-0387-2 Kinney, 2002, Perioperative management of pheochromocytoma, J Cardiothorac Vasc Anesth, 16, 359, 10.1053/jcan.2002.124150 Kinney, 2000, Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection, Anesth Anal, 91, 1118 Proye, 1989, Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients, Surgery, 106, 1149 Lebuffe, 2005, The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas, Anaesthesia, 60, 439, 10.1111/j.1365-2044.2005.04156.x Inabnet, 2000, Pheochromocytoma: inherited associations, bilaterality, and cortex preservation, Surgery, 128, 1007, 10.1067/msy.2000.110846 Shen, 2010, One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy, Arch Surg, 145, 893, 10.1001/archsurg.2010.159 Walz, 2006, Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients, World J Surg, 30, 899, 10.1007/s00268-005-0373-6 Ippolito, 2008, Safety of laparoscopic adrenalectomy in patients with large pheochromocytomas: a single institution review, World J Surg, 32, 840, 10.1007/s00268-007-9327-5 Kercher, 2005, Laparoscopic curative resection of pheochromocytomas, Ann Surg, 241, 919, 10.1097/01.sla.0000164175.26785.06 Shen, 2010, One hundred and two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy, Arch Surg, 145, 893, 10.1001/archsurg.2010.159 Neumann, 1999, Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma, J Clin Endocrinol Metab, 84, 2608 Ahlman, 2006, Malignant pheochromocytoma: state of the field with future projections, Ann N Y Acad Sci, 1073, 449, 10.1196/annals.1353.049 Nomura, 2009, Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy, J Clin Endocrinol Metab, 94, 2850, 10.1210/jc.2008-2697